Back to search

Article

Targeting LINC00152 activates cAMP/Ca <sup>2+</sup> /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancer

2023-11-05

Abstract excerpt

Tamoxifen has been the mainstay therapy to treat early, locally advanced, and metastatic estrogen receptor-positive (ER+) breast cancer, constituting around 75% of all cases. However, emergence of resistance is common, necessitating the identification of novel therapeutic targets. Here, we demonstrated that long-noncoding RNA LINC00152 confers tamoxifen resistance via blocking tamoxifen-induced ferroptosis, an iro...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
33fc0934-d0e1-52db-887e-defac624c83a
DOI
10.1101/2023.11.05.565697
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Targeting LINC00152 activates cAMP/Ca <sup>2+</sup> /ferroptosis axis and overcomes tamoxifen resistance in ER+ breast cancerDOI 10.1101/2023.11.05.565697
Select a neighboring publication to make it the new centre.